ImpediMed (IPD) EGM 2026 summary

Opening remarks and agenda

• Chair welcomed shareholders, acknowledged traditional land owners, and confirmed quorum for the meeting.

• Directors and executives were introduced, both in-person and online.

• Purpose of the meeting was to seek shareholder approval for all elements of a AUD 15.2 million capital raising.

Specific resolutions to be voted on

• Ratification of tranche one placement shares and approval for tranche one options.

• Approval for tranche two securities and share purchase plan (SPP) securities.

• Approval to issue commitment options to the underwriter.

• Approval to issue director placement securities for each director.

Strategic initiatives and plans

• Capital raised will partially prepay debt, saving AUD 0.7 million in annual interest.

• Funds to be deployed into high-growth markets: breast cancer-related lymphedema, heart health, and weight management.

• Cost base reset with AUD 5 million in annualized cost reductions, net of reinvestment in revenue-generating functions.

• Expectation to reach operating cash flow breakeven by second half of FY2028, assuming full exercise of options.